![Autoantibody Adds Fuel to COVID-19 "Firestorm" of Inflammation, Blood Clots](https://cdn.clinicallabmanager.com/assets/articleNo/25819/aImg/47904/autoantibody-adds-fuel-to-covid-19-firestorm-of-inflammation-blood-clots-s.jpg "Autoantibody Adds Fuel to COVID-19 "Firestorm" of Inflammation, Blood Clots")
Autoantibody Adds Fuel to COVID-19 "Firestorm" of Inflammation, Blood Clots
Michigan Medicine - University of Michigan | July 20, 2021
The finding will likely help physicians develop targeted therapies for future COVID-19 patients
Inflammation
Rare COVID-19 Response in Children Explained
Yale University | May 19, 2021
Researchers examine why one in 1,000 children with COVID-19 experience multisystem inflammatory response
New Insights on Inflammation in COVID-19
Wiley | April 21, 2021
Study examines the key differences between severe inflammation in COVID-19 vs cytokine storm
Crohn’s Disease May Be Caused by Immune Signaling Failure
The Scripps Research Institute | April 9, 2021
How T cells in the small intestine protect themselves from bile acids point to the possibility of targeted treatments for Crohn's
Researchers Identify Biomarkers That Predict Survival in Cervical Cancer
Miriam Bergeret, MSc | January 8, 2021
The results could help inform treatment decisions, potentially improving survival rates
Fully Automated High-Plex Proteomics to Enable Accelerated Immune Medicine
Clinical Lab Manager | October 28, 2020
Join Clinical Lab Manager and our panel of experts as we discuss how high-plex automated immunoassays facilitate critical discoveries in immune medicine, accelerating the development of advanced therapeutics across disciplines
Blood Test Could Identify COVID-19 Patients at Risk of 'Cytokine Storm' Hyperinflammation
University of Southampton | October 15, 2020
Researchers have identified a blood profile that could help identify COVID-19 patients at greatest risk of deterioration and direct them towards trials of specific treatments that could modify their immune systems' responses
FDA Emergency Use Authorization Awarded to the Beckman Coulter Access IL-6 Test
Beckman Coulter Diagnostics | October 5, 2020
The Access Interleukin-6 (IL-6) assay is designed to assist physicians in the identification of severe inflammatory response in COVID-19 patients
Scipher Medicine and Galapagos Sign Collaboration in Inflammatory Bowel Disease
Galapagos NV | August 13, 2020
Partnership combines molecular patient data, AI-based methods to identify novel targets and pathways
New Neuroinflammation Discovery Services Offer Advanced Insight into Chronic Pain
Cellectricon | May 21, 2020
Cellectricon offers fully validated in vitro disease models including human iPSC-derived neuronal cultures, cell lines, and native neuronal cultures